NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Shares of Viatris Inc. VTRS slipped 1.07% to $9.24 Wednesday, on what proved to be an all-around mixed trading session for ...

The investigation focuses on the propriety of Viatris' disclosures to its investors about the FDA's inspections of the company's manufacturing facility in Indore, India.

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VIATRIS INC. (VTRS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ETCompany ParticipantsScott Smith - Chief ...

Viatris Inc. missed sales/EPS estimates with 2025 guidance showing challenges like a $385M EBITDA hit. Learn why experts suggest avoiding VTRS stock.

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share ...

Viatris launches review, plans share buybacks. CEO outlines strategy for cost structure and remediation efforts.